Domain Associates is a venture capital firm with an exclusive focus on life sciences, investing in biopharmaceutical, medical device, diagnostic, and healthcare IT companies. Founded in 1985, the firm has managed over $2.8 billion in assets and backed more than 194 portfolio companies resulting in 90 IPOs and 110 M&A events.
36% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $34.2M (across 84 rounds with reported amounts).
Portfolio
63
Fund Size
$163.6M
Top Stage
Series B
Last 12 Mo
0
Team
DL
Debra Liebert
Managing Director
JB
Jim Blair
Partner
KK
Kim Kamdar
Partner
NV
Nicole Vitullo
Partner
NS
Nimesh S. Shah
Partner
BH
Brian Halak
Biotech investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
90 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| AAntios Therapeutics, Inc. | Series B | $96M | Apr 2021 |
| AAntios Therapeutics, Inc. | Series B | $96M | Jan 2021 |
| EExalys Therapeutics Inc. | Series A | $15M | Jul 2020 |
 Aspen Neuroscience | Series A | $70M | Apr 2020 |
 Omniome | Series C | $60M | Jan 2020 |
| Aspen Neuroscience | Seed | $6.5M | Dec 2019 |
 Sera Prognostics | Series D | $36M | Nov 2019 |
| Sera Prognostics | Series D | $36M | Jan 2019 |
 Milestone Pharmaceuticals | Series C | $55M | Aug 2017 |
 Adynxx | Series B | $16M | Jan 2017 |
| Sera Prognostics | Series C | $40M | Jan 2017 |
 Syndax Pharmaceuticals | Series C | $80M | Aug 2015 |
 Afferent Pharmaceuticals | Series C | $55M | Jul 2015 |
 CoLucid Pharmaceuticals | Series C | $37.1M | Jan 2015 |
 BioNano Genomics | Series C | $53M | Nov 2014 |
 Fractyl | Series C | $40M | Sep 2014 |
| TTwelve, Inc. | Unknown | $9.1M | Jan 2014 |
 Novadigm Therapeutics | Series B | $14M | Oct 2013 |
 Otonomy | Series C | $45.9M | Sep 2013 |
| DDicerna | Unknown | $60M | Jul 2013 |
 aTyr Pharma | Series D | $59M | Jul 2013 |
 Dicerna Pharmaceuticals | Series C | $60M | Jan 2013 |
 RightCare Solutions | Series A | $1.8M | Oct 2012 |
 IntegenX | Series C | $40M | Dec 2011 |
| Sera Prognostics | Ipo | $75M | Jan 2011 |
Page 1 of 4
Top Co-Investors
InterWest Partners13 shared
Frazier Healthcare Partners9 shared
Canaan Partners9 shared
Hercules Capital, Inc.8 shared
OrbiMed7 shared
ARCH Venture Partners6 shared
Pappas Capital6 shared
Health Catalyst Capital5 shared
Sofinnova Partners5 shared
Novo Holdings A/S4 shared
Versant Ventures4 shared
Abingworth LLP4 shared
Scale Venture Partners4 shared
Pivotal Life Sciences3 shared
Axon Partners Group3 shared
Osage University Partners3 shared
Alta Partners3 shared
aMoon3 shared
Delos Capital3 shared
Forward Partners3 shared
Last updated: 7 September 2026